Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.


TSX:BCT - Post by User

Bullboard Posts
Post by ValueHunter92on Apr 05, 2016 12:16pm
127 Views
Post# 24732467

As previously mentionned

As previously mentionned

As previously mentionned, after being criticized by obvious amateurs,

Their is way enough right now to involve a major finishing the trial;
Even more, major could just buy the whole company out and for 60 - 80 millions he has 100% right to commercialize the product in case of positive final outcome, reaching by the way a multibillion market annually.

Again as I already said, I have contact with retired FDA people and they confirmed me that it's highly likely to happens based on the previous publications

So you can bash however you want, when the PPS going to be around 70cent to 1$, remember what I told you, and remember the agressive day traders that dind't understood a single concept of pharma industry.

Still in with average 28,5 cent, ain't selling 1 share before 58-60 cent minimally, because that's it's market value right now...

Regards

Dr. Shreiber

Bullboard Posts